Nagendran Sukumar 内部人交易：近期 SEC Form 4 交易
过去 18 个月，Nagendran Sukumar（CIK 1665124）在 1 家公司共报告 17 笔 SEC Form 4 内部人交易（最近一笔 2026-07-10）。
| 日期 | 公司 | 身份 | 类型 | 股数 | 市值 |
|---|---|---|---|---|---|
| 2026-07-10 | Taysha Gene Therapies, Inc. (TSHA) | President and Head of R&D | 卖出 | 200,000 | $1.2M |
| 2026-04-13 | Taysha Gene Therapies, Inc. (TSHA) | President and Head of R&D | 买入 | 19,021 | $32,526 |
| 2026-04-13 | Taysha Gene Therapies, Inc. (TSHA) | President and Head of R&D | 卖出 | 200,000 | $892,000 |
| 2026-01-27 | Taysha Gene Therapies, Inc. (TSHA) | President and Head of R&D | 卖出 | 89,132 | $423,377 |
| 2026-01-27 | Taysha Gene Therapies, Inc. (TSHA) | President and Head of R&D | 卖出 | 26,918 | $124,092 |
| 2026-01-14 | Taysha Gene Therapies, Inc. (TSHA) | President and Head of R&D | 买入 | 111,324 | $77,927 |
| 2026-01-14 | Taysha Gene Therapies, Inc. (TSHA) | President and Head of R&D | 买入 | 88,676 | $151,636 |
| 2026-01-14 | Taysha Gene Therapies, Inc. (TSHA) | President and Head of R&D | 卖出 | 200,000 | $942,000 |
| 2026-01-14 | Taysha Gene Therapies, Inc. (TSHA) | President and Head of R&D | 买入 | 427,000 | $0 |
| 2025-12-01 | Taysha Gene Therapies, Inc. (TSHA) | President and Head of R&D | 买入 | 70,172 | $49,120 |
| 2025-12-01 | Taysha Gene Therapies, Inc. (TSHA) | President and Head of R&D | 买入 | 39,953 | $68,320 |
| 2025-12-01 | Taysha Gene Therapies, Inc. (TSHA) | President and Head of R&D | 卖出 | 110,125 | $523,094 |
| 2025-12-01 | Taysha Gene Therapies, Inc. (TSHA) | President and Head of R&D | 买入 | 260,047 | $444,680 |
| 2025-12-01 | Taysha Gene Therapies, Inc. (TSHA) | President and Head of R&D | 卖出 | 260,047 | $1.2M |
| 2025-09-12 | Taysha Gene Therapies, Inc. (TSHA) | President and Head of R&D | 买入 | 41,150 | $28,805 |
| 2025-09-12 | Taysha Gene Therapies, Inc. (TSHA) | President and Head of R&D | 卖出 | 200,000 | $646,000 |
| 2025-08-22 | Taysha Gene Therapies, Inc. (TSHA) | President and Head of R&D | 卖出 | 57,054 | $162,604 |
来源：SEC Form 4 申报文件 · 截至 2026-07-10